Accessibility Menu
International Stem Cell logo

International Stem Cell(OTC) ISCO

Current Price$0.31
Market Cap$2.51MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2007)-100%
5 Year-48%
1 Year+108%
1 Month+76%
International Stem Cell last closing stock price
MetricPriceDate
Last closeUSD 0.312026-07-24
International Stem Cell stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+74.44%USD 0.182026-07-17
1 month+76.31%USD 0.182026-06-24
3 month+124.29%USD 0.142026-04-22
Year to date+124.29%USD 0.142025-12-31
1 year+107.81%USD 0.152025-07-24
3 year+138.87%USD 0.132023-07-25
5 year-47.67%USD 0.602021-07-23
Since inception-99.92%USD 405.002007-01-09

International Stem Cell Financials at a Glance

Market Cap

$2.51MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$9.29M

Net Income (TTM)

-$382.00K

EPS (TTM)

-$0.06

P/E Ratio

-5.32

Dividend

$0.00

Beta (Volatility)

0.27 (Low)

Price

$0.31

Volume

73,028

Open

$0.30

Previous Close

$0.31

Daily Range

$0.27 - $0.32

52-Week Range

$0.12 - $0.32

Estimated Earnings Date

Aug 15, 2025

ISCO News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About International Stem Cell

International Stem Cell helps researchers and doctors study and treat diseases. Its cell products support medical research and skincare. The company’s work aims to improve health for patients and scientists worldwide.

Lab Bench to Beauty Shelf: What International Stem Cell Sells

  • Biomedical Research Products (93.4% of revenue): Human cell cultures and reagents for disease research, mainly sold to labs and research institutions.
  • Anti-Aging Skincare (6.6% of revenue): Skincare products using cell-based ingredients, sold online and through professionals to consumers.
  • Therapeutic Research (no commercial revenue): Neural stem cell therapies in development for Parkinson’s disease and brain injuries, targeting future clinical use.

Growth Spurts and Strategic Moves

  • Expanded product lines in biomedical and skincare segments in 2025.
  • Opened a manufacturing facility in Frederick, Maryland, and consolidated R&D in San Diego in 2025.
  • Formed research collaborations with Yale, Tulane, University of South Florida, UC San Diego, Scripps, and Sanford Burnham Prebys (2023–2025).
  • Entered European and Asian markets through distributors and OEM partners before 2025.

Why International Stem Cell Is a Bit Different

The company’s stem cell technology avoids using fertilized embryos, addressing ethical concerns. Its products reach global research labs and clinics through direct sales and partners. Manufacturing follows strict quality standards, supporting both research and future therapies.

Five Things You Need to Know

  • Product sales were $9.1 million in 2025, flat from 2024.
  • Biomedical segment made up 93.4% of 2025 revenue; skincare was 6.6%.
  • Gross profit margin was 56% in 2025, down from 59% in 2024.
  • One customer accounted for 54% of total sales in 2025.
  • Net loss was $418,000 in 2025, up from $209,000 in 2024.

Bottom Line

International Stem Cell has diversified from research tools to skincare and clinical development. The company faces financial challenges but continues to adapt and expand its product reach.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

33

CEO

Andrey Semechkin, PhD

Website

www.internationalstemcell.com

Headquarters

San Diego, CA 92131, US

ISCO Financials

Key Financial Metrics (TTM)

Gross Margin

56.98%

Operating Margin

-2.61%

Net Income Margin

-4.11%

Return on Equity

9.58%

Return on Capital

N/A

Return on Assets

-7.44%

Earnings Yield

-18.80%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.51MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

8.00M

Volume

73.03K

Avg. Volume

8.10K

Financials (TTM)

Gross Profit

$5.29M

Operating Income

-$242.00K

EBITDA

-$44.00K

Operating Cash Flow

-$98.00K

Capital Expenditure

-$61.00K

Free Cash Flow

-$159.00K

Cash & ST Invst.

$933.00K

Total Debt

$3.52M

International Stem Cell Performance Analysis

International Stem Cell annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 8,180,00014.0%
20232023-12-31USD 7,789,000-4.8%
20242024-12-31USD 9,085,00016.6%
20252025-12-31USD 9,100,0000.2%
International Stem Cell sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3014.9%
Q32025-09-30-3.2%
Q42025-12-31-9.0%
Q12026-03-317.4%
International Stem Cell annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.04-63.9%
20232023-12-31USD -0.02-60.4%
20242024-12-31USD -0.0359.1%
20252025-12-31USD -0.05100.0%
International Stem Cell sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30126.3%
Q32025-09-30-16.7%
Q42025-12-31-577.1%
Q12026-03-3117.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$2.32M

+8.7%

Gross Profit

$1.36M

+19.7%

Gross Margin

58.79%

N/A

Market Cap

$2.51MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$76.16K

N/A

Employees

33

N/A

Net Income

-$220.00K

+14.1%

EBITDA

-$156.00K

+2.5%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$933.00K

-35.7%

Total Debt

$3.52M

-14.0%

Accounts Receivable

$843.00K

-0.9%

Inventory

$1.77M

+40.9%

Long Term Debt

$0.00

-100.0%

Short Term Debt

$3.52M

-7.2%

Return on Assets

-7.44%

N/A

Return on Invested Capital

-2.88%

N/A

Free Cash Flow

$98.00K

-55.9%

Operating Cash Flow

$121.00K

-46.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
VCNXVaccinex, Inc.
$1.18+0.00%
BMNDFBiomind Labs Inc.
$0.05+0.00%
EVFMEvofem Biosciences, Inc.
$0.01-4.76%
NSTMNovelStem International Corp.
$0.01+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
SOFISoFi Technologies
$16.46-0.01%
FFord Motor Company
$14.37+0.02%
AALAmerican Airlines Group
$14.48+0.07%

Questions About ISCO

What is the current price of International Stem Cell?

International Stem Cell is trading at $0.31 per share.

What is the 52-week range for International Stem Cell?

Over the past 52 weeks, International Stem Cell has traded between $0.12 and $0.32.

How much debt does International Stem Cell have?

As of the most recent reporting period, International Stem Cell reported total debt of $3.52M.

How much cash does International Stem Cell have on hand?

International Stem Cell reported $933.00K in cash and cash equivalents in its most recent financial results.

What is International Stem Cell’s dividend yield?

International Stem Cell does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services